Valproic acid and fatalities in children: A review of individual case safety reports in VigiBase

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Star, Kristina ^a   Edwards, I Ralph ^a   Choonara, Imti ^b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT;

ANEMIA; APNEA; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW DEPRESSION; BRAIN DISEASE; BRAIN EDEMA; CHILD; COMA; CONSCIOUSNESS DISORDER; DATA BASE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG SAFETY; EPILEPSY; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERAMMONEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; METABOLIC ACIDOSIS; OUTCOME ASSESSMENT; PANCREATITIS; PNEUMONIA; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SEPSIS; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; LIVER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; CHILD; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPILEPSY; HUMANS; LIVER; VALPROIC ACID;

EID: 84907841730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108970     Document Type: Review

References (38)

1. Colletti RB, Trainer TD, Krawisz BR (1986) Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr 5: 990-4.
2. Anderson M, Choonara I (2010) A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. Arch Dis Child 95: 731-8.
3. Donat JF, Bocchini JA Jr, Gonzalez E, Schwendimann RN (1979) Valproic acid and fatal hepatitis. Neurology 29: 273-4.
4. Suchy FJ, Balistreri WF, Buchino JJ, Sondheimer JM, Bates SR, et al. (1979) Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 300: 962-6.
5. Dreifuss FE, Sandlli N, Langer DH, Sweeney KP, Moline KA, et al. (1987) Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379-85.
6. Scheffner D, Konig S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, et al. (1988) Fatal liver failure in 16 children with valproate therapy. Epilepsia 29: 530 -42.
7. Dreifuss FE, Langer DH, Moline KA, Maxwell JE (1989) Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 39: 201-7.
8. Grauso-Eby NL, Goldfarb O, Feldman-Winter LB, McAbee GN (2003) Acute pancreatitis in children from Valproic acid: case series and review. Pediatr Neurol 28: 145-8.
9. Clarkson A, Choonara I (2002) Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 87: 462-6.
10. Lindquist M (2008) Vigibase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal 42: 409-19.
11. Star K, Noren GN, Nordin K, Edwards IR (2011) Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 34: 415-28.
12. Norén GN, Orre R, Bate A, Edwards IR (2007) Duplicate detection in adverse drug reaction surveillance. Data Mining and Knowledge Discovery 14: 305-28.
13. Norén GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22: 57-69.
14. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, et al. (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315-21.
15. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH (1978) One drug for epilepsy. BMJ 1: 474-6.
16. Gopaul S, Farrell K, Abbott F (2003) Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 44: 322-8.
17. Koenig SA, Buesing D, Longin E, Oehring R, Häussermann P, et al. (2006) Valproic acid-induced hepatopathy: Nine new fatalities in Germany from 1994 to 2003. Epilepsia 47: 2027-31.
18. Schmid MM, Freudenmann RW, Keller F, Connemann BJ, Hiemke C, et al. (2013) Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 46: 63-8.
19. Chapman SA, Wacksman GP, Patterson BD (2001) Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy 21: 1549-60.
20. Sinclair DB, Berg M, Breault R (2004) Valproic acid-induced pancreatitis in childhood epilepsy: case series and review. J Child Neurol 19: 498-502.
21. Werlin SL, Fish DL (2006) The spectrum of valproic acid-associated pancreatitis. Pediatrics 118: 1660-3.
22. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, et al. (2006) Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47: 1136-43.
23. Acharya S, Bussei JB (2000) Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 22: 62-5.
24. Kose G, Arhan E, Unal B, Ozaydin E, Guven A, et al. (2009) Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol 24: 1493-8.
25. Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, et al. (2006) Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47:1232-6.1232-6.
26. Kishi T, Fujita N, Kawaguchi H, Ishimae M, Watanabe K, et al. (1994) Bone marrow suppression induced by high dose valproic acid. Arch Dis Child 71: 153-5. 153-5.
27. Rajantie J, Kajosaari M, Ylitalo V (1992) Fatal pancytopenia during high-dose valproate monotherapy. Eur J Pediatr 151: 619.
28. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, et al. (1999) Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 353: 2190-4.
29. Koh MJ-A, Tay Y-K (2010) Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J AM ACAD DERMATOL 62: 54-60.
30. Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Caveat document, http://www.who-umc.org/graphics/25300.pdf. Accessed 26 Sep 2013.
31. Fletcher AP (1991) Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 84: 341-4.
32. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29: 385-96.
33. Cvitanovic-Sojat L, Bielen I, Sruk A, Kosicek M, Planjar-Prvan M, et al. (2010) Social and medical care of preschool children with epilepsy in Croatia: population-based survey. Eur J Paediatr Neurol 14: 73 -7.
34. Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, et al. (2010) Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 51: 789-96.
35. Arencibia ZB, Leyva AL, Pena YM, Reyes AR, Napolez MA, et al. (2012) Access to antiepileptic drug therapy in children in Camaguey Province, Cuba. Int J Pharm Pract 20: 390-4.
36. Berg AT, Levy SR, Testa FM, Shinnar S (1999) Treatment of newly diagnosed pediatric epilepsy: a community-based study. Arch Pediatr Adolesc Med 153: 1267-71.
37. Talaat F, El-Rabbat M, Atef M, Shaker E, Mohammed H (2009) Prevalence of epilepsy in school children in El-Many al Island. Egypt J Neurol Psychiatr Neurosurg 46: 19-32.
38. Electronic Medicines Compendium. Summary of Product Characteristics for Epilim Chronosphere. 2014; http://www.medicines.org.uk/eme/medicine/ 26144. Accessed July 09 2014.